Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025246 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
A Phase 2 study of Gastrointestinal Stromal Tumor, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT00025246 is a Phase 2 study of Gastrointestinal Stromal Tumor that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 89 participants, above the 59-participant average among 8 other Gastrointestinal Stromal Tumor trials with a reported enrollment target (51% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00025246, a Phase 2 study of Gastrointestinal Stromal Tumor, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
Study Locations (1)
North Carolina
- American College of Surgeons Oncology Group - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025246
The ClinicalTrials.gov registry entry for NCT00025246 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 8 other Gastrointestinal Stromal Tumor trials with a reported enrollment target (51% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Stromal Tumor appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00025246 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00025246 about?
NCT00025246 is a clinical study titled "Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery". This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
What is the current status of trial NCT00025246?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2001-09.
What conditions does trial NCT00025246 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumor.
What interventions are being tested in trial NCT00025246?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00025246?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025246 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
COMPLETED · Phase 2
-
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
COMPLETED · Phase 2
-
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.